Menu

TS Picks: February 24, 2016

High-profile stem cell research scandal; forthcoming direct-to-consumer genetics apps; GINA and life insurance

Feb 24, 2016
Tracy Vence

Human embryonic stem cellsWIKIMEDIA, NISSIM BENVENISTY

Selections from The Scientist’s reading list:
 

  • “As an outsider—young, female, and not an established stem-cell biologist—[Haruko] Obokata, the newspapers argued, was unhindered by conventional notions of what cells can and cannot do. Her fresh perspective, coupled with dogged work and natural genius, had conspired to create one of the great scientific breakthroughs of the twenty-first century.” —The New Yorker on STAP and stem cell research
     
  • MIT Technology Review this month named direct-to-consumer genetics apps, such as Helix’s forthcoming product, one of the top 10 breakthroughs of the year. (CRISPR and genetically engineered immune cells also made Tech Review’s 2016 list.)
     
  • While the Genetic Information Nondiscrimination Act (GINA) protects people from discrimination based on their genetics by employers and health insurers, its reach may be limited. Fast Company spoke with a woman who was reportedly denied life-insurance coverage because she carries the cancer-associated BRCA1 mutation and has a family history of the disease.

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.